Literature DB >> 20543188

Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images.

Nelleke Tolboom1, Wiesje M van der Flier, Jolanda Boverhoff, Maqsood Yaqub, Mike P Wattjes, Pieter G Raijmakers, Frederik Barkhof, Philip Scheltens, Karl Herholz, Adriaan A Lammertsma, Bart N M van Berckel.   

Abstract

OBJECTIVE: To evaluate visual assessment of [(11)C]PIB and [(18)F]FDDNP PET images as potential supportive diagnostic markers for Alzheimer's disease (AD).
METHODS: Twenty-one AD patients and 20 controls were included. Parametric [(11)C]PIB and [(18)F]FDDNP global binding potential (BP(ND)) images were visually rated as 'AD' or 'normal.' Data were compared with ratings of [(18)F]FDG PET images and MRI-derived medial temporal lobe atrophy (MTA) scores. Inter-rater agreement and agreement with clinical diagnosis were assessed for all imaging modalities. In addition, cut-off values for quantitative global [(11)C]PIB and [(18)F]FDDNP BP(ND) were determined. Visual ratings were compared with dichotomised quantitative values.
RESULTS: Agreement between readers was excellent for [(11)C]PIB, [(18)F]FDDNP and MTA (Cohen kappa kappa> or =0.85) and moderate for [(18)F]FDG (kappa=0.56). The highest sensitivity was found for [(11)C]PIB and [(18)F]FDG (both 1.0). The highest specificity was found for MTA (0.90) and [(11)C]PIB (0.85). [(18)F]FDDNP had the lowest sensitivity and specificity (0.67 and 0.53, respectively). The cut-off for quantitative [(11)C]PIB BP(ND) was 0.54 (sensitivity and specificity both 0.95) and for [(18)F]FDDNP BP(ND) 0.07 (sensitivity 0.80, specificity 0.73). Agreement between quantitative analyses and visual ratings was excellent for [(11)C]PIB (kappa=0.85) and fair for [(18)F]FDDNP (kappa=0.40).
CONCLUSION: Visual assessment of [(11)C]PIB images was straightforward and accurate, showing promise as a supportive diagnostic marker for AD. Moreover, [(11)C]PIB showed the best combination of sensitivity and specificity. Visual assessment of [(18)F]FDDNP images was insufficient. The quantitative analysis of [(18)F]FDDNP data showed a considerably higher diagnostic value than the visual analysis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20543188     DOI: 10.1136/jnnp.2009.194779

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  21 in total

Review 1.  Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia.

Authors:  William E Klunk
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

2.  [F-18]FDDNP microPET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-Aβ antibody treatment.

Authors:  Edmond Teng; Vladimir Kepe; Sally A Frautschy; Jie Liu; Nagichettiar Satyamurthy; Fusheng Yang; Ping-Ping Chen; Graham B Cole; Mychica R Jones; Sung-Cheng Huang; Dorothy G Flood; Stephen P Trusko; Gary W Small; Gregory M Cole; Jorge R Barrio
Journal:  Neurobiol Dis       Date:  2011-05-13       Impact factor: 5.996

3.  Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET.

Authors:  Rik Ossenkoppele; Nelleke Tolboom; Jessica C Foster-Dingley; Sofie F Adriaanse; Ronald Boellaard; Maqsood Yaqub; Albert D Windhorst; Frederik Barkhof; Adriaan A Lammertsma; Philip Scheltens; Wiesje M van der Flier; Bart N M van Berckel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-23       Impact factor: 9.236

4.  Amyloid and its association with default network integrity in Alzheimer's disease.

Authors:  Sofie M Adriaanse; Ernesto J Sanz-Arigita; Maja A A Binnewijzend; Rik Ossenkoppele; Nelleke Tolboom; Daniëlle M E van Assema; Alle Meije Wink; Ronald Boellaard; Maqsood Yaqub; Albert D Windhorst; Wiesje M van der Flier; Philip Scheltens; Adriaan A Lammertsma; Serge A R B Rombouts; Frederik Barkhof; Bart N M van Berckel
Journal:  Hum Brain Mapp       Date:  2012-12-14       Impact factor: 5.038

5.  Disclosure of amyloid imaging results to research participants: has the time come?

Authors:  Jennifer H Lingler; William E Klunk
Journal:  Alzheimers Dement       Date:  2013-02-13       Impact factor: 21.566

6.  Visual-statistical interpretation of (18)F-FDG-PET images for characteristic Alzheimer patterns in a multicenter study: inter-rater concordance and relationship to automated quantitative evaluation.

Authors:  T Yamane; Y Ikari; T Nishio; K Ishii; K Ishii; T Kato; K Ito; D H S Silverman; M Senda; T Asada; H Arai; M Sugishita; T Iwatsubo
Journal:  AJNR Am J Neuroradiol       Date:  2013-08-01       Impact factor: 3.825

7.  In vivo assessment of amyloid-β deposition in nondemented very elderly subjects.

Authors:  Chester A Mathis; Lewis H Kuller; William E Klunk; Beth E Snitz; Julie C Price; Lisa A Weissfeld; Bedda L Rosario; Brian J Lopresti; Judith A Saxton; Howard J Aizenstein; Eric M McDade; M Ilyas Kamboh; Steven T DeKosky; Oscar L Lopez
Journal:  Ann Neurol       Date:  2013-04-17       Impact factor: 10.422

8.  Molecular interactions of Alzheimer's biomarker FDDNP with Aβ peptide.

Authors:  Christopher Lockhart; Dmitri K Klimov
Journal:  Biophys J       Date:  2012-12-05       Impact factor: 4.033

9.  Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches.

Authors:  Ann D Cohen; Wenzhu Mowrey; Lisa A Weissfeld; Howard J Aizenstein; Eric McDade; James M Mountz; Robert D Nebes; Judith A Saxton; Beth Snitz; Steven Dekosky; Jeff Williamson; Oscar L Lopez; Julie C Price; Chester A Mathis; William E Klunk
Journal:  Neuroimage       Date:  2013-01-24       Impact factor: 6.556

10.  Inter-rater variability of visual interpretation and comparison with quantitative evaluation of 11C-PiB PET amyloid images of the Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI) multicenter study.

Authors:  Tomohiko Yamane; Kenji Ishii; Muneyuki Sakata; Yasuhiko Ikari; Tomoyuki Nishio; Kazunari Ishii; Takashi Kato; Kengo Ito; Michio Senda
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-13       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.